

LONDON . PARIS . MUNICH . NEW YORK . GENEVA . NEW DELHI



Please find our Research on Bloomberg BRYG <GO>)

8th April 2016

| | Last close | Daily chg (%) | Chg YTD (%) |
|------------------|---------------|------------------|----------------|
| Indices | | | |
| Dow Jones | 17541.96 | -0.98% | +0.67% |
| S&P 500 | 2041.91 | -1.20% | -0.10% |
| Nasdaq | 4848.37 | -1.47% | -3.18% |
| Nikkei | 15821.52 | +0.46% | -17.25% |
| Stoxx 600 | 328.097 | -0.77% | -10.31% |
| CAC 40 | 4245.91 | -0.90% | -8.44% |
| Oil /Gold | | | |
| Crude WTI | 37.37 | -1.01% | +0.46% |
| Gold (once) | 1240.28 | +1.48% | +16.75% |
| Currencies/Rates | | | |
| EUR/USD | 1.1382 | +0.07% | +4.78% |
| EUR/CHF | 1.0868 | -0.17% | -0.06% |
| German 10 years | 0.087 | -24.90% | -86.31% |
| French 10 years | 0.365 | -3.16% | -62.79% |
| Euribor | - | +-% | +-% |

Economic releases:

Date

8th-Apr CH - Unemployment rate Mar. (3.5%)

DE -Trade Balance Feb. (20.3b A vs. 18b E)

GB -Manuf Prod. Feb. (-0.7% E y/y)

GB - Total trade Balance

US - Wholesale Inventories Feb. (-0.2% m/m)

US -Baker Hughes Rig Count.

Upcoming BG events

| Date | |
|----------|---|
| 8th-Apr | VINCI (BGLuxembourg roadshow with CFO) |
| 12th-Apr | DBV TECH. (BG Paris roadshow with CEO) |
| 20th-Apr | REMY COINTREAU (BG Paris breakfast with CFO) |
| 22nd-Apr | PERNOD RICARD (BG Paris roadshow with Head of IR) |
| 28th-Apr | ORPEA (BG Luxembourg with IR) |
| 28th-Apr | ORPEA (BG Luxembourg with IR) |

Recent reports :

Date

| 6th-Apr | EDP Renovaveis : Renewables, what else? |
|----------|--|
| 4th-Apr | GAMELOFT: Nothing to gain by tendering your GF shares now! |
| 29th-Mar | IPSEN Cabozantinib makes Ipsen a different story |
| 23rd-Mar | AMOEBA It's getting closer! |
| 23rd-Mar | Feedback from our TMT Conference in Paris |
| 22nd-Mar | LUXOTTICA: Turbulence almost over, make the most of it! |



BG's Wake Up Call

NICOX

CORPORATE, Fair Value EUR14

A visible decrease in pressure... (full report released today)

We are initiating coverage of Nicox with a Fair Value of EUR14.0. In our view the market is clearly underestimating the potential of latanoprostene bunod (LBN) in glaucoma (BG peak sales: around EUR600m from a conservative stance) and the group's risk-reward profile is fairly attractive following the share-price decline.

WIRECARD

BUY-Top Picks, Fair Value EUR52 (+59%)

Conference call feedback – Key points to take away

No surprises regarding the FY15 earnings released yesterday morning. For FY16, we are already at the high end of the recently increased EBITDA guidance and we confirm our estimate. P/E of 17.9x vs. restated EPS growth of +38% in 2016e. The negative share price reaction yesterday afternoon is inconsistent. We maintain our Buy rating and FV of EUR52. The stock is on our Q2 Top Pick list.

BREWERS

Heineken remains a buy

Yesterday we lowered our recommendation for some of the brewers, which leaves Heineken as the only brewer that we consider worthwhile buying.

In brief...

BIOMÉRIEUX, Four panels now approved for use with FilmArray Torch ASTRAZENECA, USD100m in externalisation revenues as AZD3293 moves to phase III

Healthcare

Nicox Price EUR7.14

A visible decrease in pressure... (full report released today) Fair Value EUR14

CORPORATE

 Bloomberg
 COX FP

 Reuters
 NCOX.LN

 12-month High / Low (EUR)
 9.9 / 6.0

 Market Cap (EURm)
 163

 Ev (BG Estimates) (EURm)
 150

 Avg. 6m daily volume (000)
 95.40

 3y EPS CAGR
 67.3%

1 M 3 M 6 M 31/12/15 Absolute perf. -0.2% -14.9% -17.8% -21.8% -4.7% Healthcare 0.4% -6.8% -10.1% DJ Stoxx 600 -3.8% -5.3% -9.1% -10.3% YEnd Dec. (EURm) 2014 2017e 2015e 2016e Sales 6.0 99 10.8 17.8 65 4% 9.3% 64 9% % change **EBITDA** -21.8 -24.4 -17.4-24.7 **EBIT** -21.8 -24.4 -17.4 -24.7 -12.1% 28.6% -41.6% % change Net income -22 9 -24 4 -17 4 -24 7 -6.7% 28.6% -41.6% % change 2014 2015e 2016e 2017e Operating margin NM NM NM NM Net margin NM MM NM MM ROE -22.0-22.3-18.9-36.6 -18 7 -15.8 -28 7 ROCE -19 1 50.6 Gearing -5.7-12.05.5 (EUR) 2014 2015e 2016e 2017e **EPS** -0.23-1.07 -0.76-1.08 % change NS 28.6% -41.6% P/E NS NS NS NS FCF yield (%) NM NM NM NM Dividends (EUR) 0.00 0.00 0.00 0.00 Div yield (%) NM NIM NM NM

We are initiating coverage of Nicox with a Fair Value of EUR14.0. In our view the market is clearly underestimating the potential of latanoprostene bunod (LBN) in glaucoma (BG peak sales: around EUR600m from a conservative stance) and the group's risk-reward profile is fairly attractive following the share-price decline.

ANALYSIS

- Why invest now? Nicox is clearly on the verge of a major turning point with the potential
 approval of latanoprostene bunod (LBN) in monotherapy, aiming to reduce intra-ocular
 pressure (IOP) in patients suffering from open-angle glaucoma or ocular hypertension (deadline
 given for the FDA's green light: 21st July 2016).
- LBN: set to trigger a future re-rating. Phase III results published in 2014 bode well and it is very probably for this reason that Nicox' partner, Valeant/Bausch+Lomb, sees peak sales potential of USD1.0bn for the product. Admittedly, our forecasts are far more conservative than the big pharma's, but we are still forecasting very high potential (~EUR600m given that 1/ LBN could be the most efficient prostaglandin analogue for reducing IOP in glaucoma, 2/ we do not expect Rho inhibitors to take the market by storm.
- Initiation with a FV of EUR14.0. Although we forecast considerable upside potential already (around 100%), our valuation could be increased massively if the FDA approves LBN and AC-170 (EUR20.0, implying upside potential of more than 190%).

NEXT CATALYSTS

 The main catalyst that we see is obviously the FDA's approval of latanoprostene bunod in monotherapy aimed at reducing intra-ocular pressure in patients suffering from open-angle glaucoma or ocular hypertension. Following this, we believe that the share should benefit from a very significant re-rating.

Click here to download



26.3x

NS

NS

15.2x

NS

NS

15.5x

NS

NS

11.1x

NS

NS

EV/Sales

EV/EBIT

EV/EBITDA



Analyst : Mickael Chane Du 33(0) 1 70 36 57 45 mchanedu@bryangarnier.com Sector Team : Eric Le Berrigaud Hugo Solvet

TMT

Wirecard Price EUR32.75

| Reuters 12-month High / Lo Market Cap (EUR) Ev (BG Estimates) (Avg. 6m daily volui 3y EPS CAGR | (EUR) | | | WDI GR VDIG.DE 4 / 31.2 4,047 3,350 849.6 28.8% |
|--|--------|--------|---------------|---|
| | 1 M | 3 M | 6 M 31 | /12/15 |
| Absolute perf. | -12.0% | -28.0% | -23.3% | -29.6% |
| Softw.& Comp. | 0.0% | -1.6% | 9.5% | -5.5% |
| DJ Stoxx 600 | -3.8% | -5.3% | -9.1% | -10.3% |
| YEnd Dec. (EURm) | 2015 | 2016e | 2017e | 2018e |
| Sales | 771.3 | 1,016 | 1,259 | 1,504 |
| % change | | 31.7% | 23.9% | 19.5% |
| EBITDA | 227 | 306 | 385 | 466 |
| EBIT | 197.4 | 270.7 | 341.1 | 413.7 |
| % change | | 37.1% | 26.0% | 21.3% |
| Net income | 163.8 | 225.9 | 287.2 | 350.1 |
| % change | | 37.9% | 27.1% | 21.9% |
| | 2015 | 2016e | 2017e | 2018 e |
| Operating margin | 25.6 | 26.6 | 27.1 | 27.5 |
| Net margin | 18.5 | 19.8 | 20.3 | 20.8 |
| ROE | 11.1 | 13.7 | 15.0 | 15.7 |
| ROCE | 29.5 | 30.7 | 33.2 | 35.2 |
| Gearing | -54.1 | -47.6 | -47.5 | -48.8 |
| (EUR) | 2015 | 2016e | 2017 e | 2018e |
| EPS | 1.33 | 1.83 | 2.33 | 2.84 |
| % change | - | 37.9% | 27.1% | 21.9% |
| P/E | 24.7x | 17.9x | 14.1x | 11.6x |
| FCF yield (%) | 3.2% | 2.9% | 4.2% | 5.6% |
| Dividends (EUR) | 0.13 | 0.14 | 0.15 | 0.16 |
| Div yield (%) | 0.4% | 0.4% | 0.5% | 0.5% |
| EV/Sales | 4.3x | 3.3x | 2.6x | 2.0x |



14.8x

17.0x

10.9x

12.4x

8.4x

9.5x

6.6x

7.4x

FV/FBITDA

FV/FBIT

Conference call feedback – Key points to take away Fair Value EUR52 (+59%)

BUY-Top Picks

No surprises regarding the FY15 earnings released yesterday morning. For FY16, we are already at the high end of the recently increased EBITDA guidance and we confirm our estimate. P/E of 17.9x vs. restated EPS growth of +38% in 2016e. The negative share price reaction yesterday afternoon is inconsistent. We maintain our Buy rating and FV of EUR52. The stock is on our Q2 Top Pick list.

ANALYSIS

- Key metrics in FY15: 1/ revenue increased by 28.3% Y/Y (+23.2% Ifl), breaking down into 63.6% from Europe (+23.9% Y/Y, +20.6% Ifl) and 36.4% from outside Europe (+39.6% Y/Y, +29.7% Ifl); 2/ transaction volumes processed stood at EUR45.2bn (+31.8% Y/Y, +30.3% Ifl), breaking down into 75.2% Europe (+26.3% Y/Y, +26.0% Ifl) and 24.8% outside Europe (+51.4% Y/Y, +46.2% Ifl); 3/ average fee per transaction of 1.6%, breaking down into 1.4% in Europe and 2.1% outside Europe; 4/ EBITDA of EUR227.3m (margin of 29.5%; last guidance of 223-232m), including a contribution of EUR3.8m in mobile payments (vs. guidance of ~EUR4m).
- Our view: Wirecard boasts the best fundamentals in the sector thanks to its positioning in e-commerce (pure-player in online payments) and emerging markets (~30%e in South East Asia). The profitability improvement was also driven by the growing proportion of large merchants in its revenue mix. Indeed, the transaction volumes processed per merchant (from EUR0.96m in 2009 to EUR2.05m in 2015) more than offset the decline in the fee per transaction (from 2.2% to 1.6%) and Wirecard's standardised and mutualised platform generates economies of scale.
- FY16 EBITDA guidance (EUR290-310m) is based on growth in the European e-commerce market and additional global growth drivers, an increase in processed transaction volumes with existing and new clients, economies of scale, and a contribution from recent acquisitions. Detailed breakdown of the mid-point (EUR300m): 1/ organic growth of 23% (seen as conservative by management); 2/ an expected EBITDA contribution from mobile payment of EUR5.0m (vs. BG est. 5.5m); 3/ EUR16.0m EBITDA contribution from the payment business of GI Retail (BG est.: EUR16.5m); and 4/ EUR4.0m combined EBITDA contribution from Provus Group and MoIP (BG est.: EUR5.2m). As a reminder, the guidance does not include any effects from the sale of Visa Europe.
- Regarding the impact of Visa Europe acquired by Visa Inc. As a reminder, this deal is valued at EUR21.2bn (closing expected in Q2 2016) with the following breakdown: a EUR16.5bn up-front payment (EUR11.5bn in cash and EUR5bn in shares) and EUR4.7bn in potential earn-outs over 4 years. Wirecard has indicated the overall impact of Wirecard's 0.5% stake in VISA Europe, namely proceeds of EUR117.1m (vs. ~EUR100m previously expected). It has the same breakdown as Visa Europe for the cash (EUR67.3m), the stock (EUR23.8m) and the earn-out contribution (EUR26.0m). It should come as a positive financial result (not the potential earn-outs but the upfront payment and the value of the shares). In Europe, in the online field, Wirecard is the substantial acquirer.
- Strong market prospects: 1/ global e-commerce growth in 2016 of 16-17% (Euromonitor/Statista); 2/ growth of the European e-commerce market of 12% for 2016 (Forrester/Statista); and 3/ growth prospects for the Asian market of 25% in 2016 (Statista).
- M&A strategy: the group has a conservative M&A policy allowing for targets of up to 10% of its revenue (no risk of capital increase). In order to be really global, management is focusing on a US market entry within 12-16 months (it could no longer remain outside), organically or via M&A on conservative multiples (it is in initial talks on potential deals but these remain in the early stages).
- Regarding Zatarra's allegations: there is no impact on operational business. People or legal
 entities behind Zatarra are not yet identified (Wirecard has legal advisors and there is still a
 research process ongoing). Once this is known, it will finally be able to sue them. The BaFin has
 started an investigation into possible market manipulation by false or misleading information.

VALUATION

- No surprises regarding the FY15 earnings released yesterday. We are making no changes to our forecasts.
- We expect restated EPS growth of 38% in FY16e (vs. +31% in FY15 and +23% in FY14) compared to a P/E of 17.9x. We see the current share price as a clear Buy opportunity.
- We maintain our Buy rating and FV of EUR52. At our FV, P/E would be 28.4x. Q2 Top Pick list.

NEXT CATALYSTS

• Q1 sales: 19th May (before trading).

Management track-record from 2010 to 2015: reported EBITDA vs. initial guidance

| 20 | 10 | 20 | 11 | 20 | 12 | 20 | 13 | 20 | 14 | 20 | 15 |
|----------------|---------------------------------|---|--|---|---|--|---|---|--|--|--|
| Init. Guid. | Rep. Fig. | Init. Guid. | Rep. Fig. | Init. Guid. | Rep. Fig. | Init. Guid. | Rep. Fig. | Init. Guid. | Rep. Fig. | Init. Guid. | Rep. Fig. |
| 70.75 | 70.0 | 04.00 | 04.4 | 103- | 400.0 | 120- | 100.0 | 160- | 470.0 | 205- | 227.2 |
| 70-75 | 13.3 | 81-89 | 84.4 | 115 | 109.2 | 130 | 126.0 | 175 | 172.9 | 225 | |
| 72.5 | 73.3 | 85.0 | 84.4 | 109.0 | 109.2 | 125.0 | 126.0 | 167.5 | 172.9 | 215.0 | 227.2 |
| | . 1 10/ | | 0.70/ | | .0.20/ | | . 0. 90/ | | . 2.20/ | | . E 70/ |
| | +1.1% | | -0.7% | | +0.2% | | +0.8% | | +3.2% | | +5.7% |
| | 0.00/ | | F 00/ | | F 00/ | | 2.40/ | | 4.00/ | | . 4.00/ |
| | -2.3% | | -5.2% | | -5.0% | | -3.1% | | -1.2% | | +1.0% |
| | Init. Guid. 70-75 72.5 | Guid. Fig. 70-75 73.3 72.5 73.3 +1.1% -2.3% | Init. Rep. Guid. 70-75 73.3 81-89 72.5 73.3 85.0 +1.1% -2.3% | Init. Guid. Rep. Fig. Init. Guid. Rep. Fig. 70-75 73.3 81-89 84.4 72.5 73.3 85.0 84.4 +1.1% -0.7% | Init. Guid. Rep. Fig. Init. Guid. Rep. Guid. Init. Fig. Guid. 70-75 73.3 81-89 84.4 103-115 72.5 73.3 85.0 84.4 109.0 +1.1% -0.7% -2.3% -5.2% | Init. Guid. Rep. Fig. Guid. Init. Fig. Guid. Rep. Guid. Fig. Guid. Init. Fig. Guid. Fig. Guid. Rep. Guid. Fig. Guid. Rep. Guid. Fig. Guid. Fig. Fig. Guid. Init. Fig. Guid. Rep. Guid. Fig. Guid. Fig. Guid. Init. Guid. Fig. Guid. Rep. Guid. Fig. Guid. Init. Guid. Fig. Guid. Rep. Guid. Fig. Guid. Fig. Guid. Init. Guid. Fig. Guid. Rep. Guid. Fig. Guid. Fig. Guid. Fig. Guid. F | Init. Rep. Guid. Fig. Guid. 109-2 120-130 130 130 125-0 130 140-2 125-0 130 140-2 125-0 130 140-2 125-0 140-2 | Init. Guid. Rep. Fig. Init. Guid. Rep. Guid. Init. Fig. Guid. Rep. Guid. Fig. Guid. Init. Guid. Rep. Guid. Fig. Guid. F | Init. Guid. Rep. Fig. Init. Guid. Rep. Guid. Init. Fig. Guid. Init. Fig. Guid. Rep. Guid. Init. Fig. Guid. | Init. Rep. Init. Rep. Guid. Fig. To.70-75 73.3 81-89 84.4 109.2 109.2 120- 120- 126.0 175- 172.9 | Init. Rep. Init. I |

Source: Bryan, Garnier & Co.

- In recent years, the group has regularly raised its EBITDA guidance (several times during the year).
- On average, it has reported a figure 2% higher than the middle of its initial range (6% higher in 2015).
- Every year, it moves slightly closer to the top-end of its initial range, and above the range for the first time in 2015e. We expect a similar scenario in 2016e (BG est. EUR306.4 vs. initial guidance range of EUR280-300m).

Click here to download



Analyst : Richard-Maxime Beaudoux 33(0) 1.56.68.75.61 rmbeaudoux@bryangarnier.com Sector Team: Thomas Coudry Gregory Ramirez Dorian Terral

Sector View

Brewers

| | 1 M | 3 M | 6 M | 31/12/15 |
|-----------------------|-------|-------|-------|----------|
| Food & Bev. | -0.1% | -0.3% | 2.4% | -4.0% |
| DJ Stoxx 600 | -3.8% | -5.3% | -9.1% | -10.3% |
| *Stoxx Sector Indices | | | | |

| Companies covered | | | | | | | |
|-------------------|----------|-------------|-------------|--|--|--|--|
| AB INBEV | | NEUTRAL | EUR109 | | | | |
| Last Price | EUR107.1 | Market Cap. | EUR172,243m | | | | |
| CARLSBERG | | SELL | DKK500 | | | | |
| Last Price | DKK622 | Market Cap. | DKK95,227m | | | | |
| HEINEKEN | | BUY | EUR79 | | | | |
| Last Price | EUR78.84 | Market Cap. | EUR45,412m | | | | |
| MOLSON COO | RS | NEUTRAL | USD97 | | | | |
| Last Price | USD92.3 | Market Cap. | USD19,779m | | | | |
| SABMILLER | | NEUTRAL | 4400p | | | | |
| Last Price | 4226.5p | Market Cap. | GBP68,528m | | | | |
| | | | | | | | |



Heineken remains a buy

Yesterday we lowered our recommendation for some of the brewers, which leaves Heineken as the only brewer that we consider worthwhile buying.

Yesterday we lowered our recommendation for SABMiller to Hold (from Buy) and for Molson Coors to Hold (from Buy); and kept our recommendation for AB InBev at Hold and for Carlsberg at Sell. Indeed on the back of the changed BG research risk free rate (1.6% vs 2.0%) and risk free rate (7% vs 6.4%), we have lowered our DCF-based fair value for AB InBev to EUR109 (vs EUR111), for Heineken to EUR79 (vs EUR83), for Carlsberg DKK500 (vs DKK520) and for Molson Coors to USD97 (vs USD101). For SABMiller the fair value of GBp4,400 is driven by the ABI offer price and remained unchanged. As a result of these fair value adjustments we have limited upside for the brewers. Indeed, AB InBev Heineken and Molson Coors are trading at fair value, SABMiller has an upside of 3% to fair value.

Although there is no upside to fair value for Heineken shares, we believe this stock is still worthwhile buying. We are summarising our buy case for the stock below.

ΔΝΔΙ ΥςΙς

- Organically Heineken is growing well with last year delivering organic revenue growth of 3.5% and organic profit growth of 6.9%. But on top of that Heineken is most likely to be the next brewer to make a significant acquisition. And acquisitions are the big value creator (or destructor in some cases) in the sector. AB InBev and Molson Coors will need a couple of years to digest the SABMiller and MillerCoors acquisitions, and Carlsberg is ruling itself out for big acquisitions. With deals like FEMSA Cerveza and Asia Pacific Breweries, Heineken's recent acquisition track record has been good. Furthermore we an estimated net debt/EBITDA of 2.2x by the end of 2016, the company has the capability to gear up. If external growth opportunities would not come along, we can expect at some stage, Heineken to start buying back to 20% that FEMSA has in the company. Indeed, FEMSA was mostly paid in shares when it sold FEMSA Cerveza to Heineken and has always made it clear that although it is a very happy shareholder of Heineken, the stake could be sold if an opportunity in its core retail and bottling business would arrive.
- Furthermore, Heineken has a well- balanced diversified geographic footprint with around 60% of operating profit from developing markets but it carries a low country specific operational risk with the highest contributors ranking Mexico (11%), Vietnam (10%), Nigeria (8%), France (7%) and the UK (6%).
- It has a strong innovation agenda with new products/packaging and extensions accounting for 9.2% of revenues in 2015 (up from a mere 3% in 2010), signalling that the company is adapting swiftly to the rapidly changing consumer environment.
- With brands like Heineken, Tecate, Tiger and Desperados, the company is leading in the international premium segment where growth and profitability are higher (see our note from March 2016 on high end beer). Indeed, Heineken is the brewer which has the highest exposure to high end beer with 36% of volumes and an estimated 60% of profits in that segment. Carlsberg's exposure to high end is 25% of volumes, for AB InBev it is 17%, for SABMiller it is 15% and for MolsonCoors it is 11%. Furthermore Heineken has the set-up (i.e. the geographic presence) to benefit further from the expected growth in import beers in emerging markets.
- Heineken is running programmes to improve the efficiency of its operations and has delivered
 on them. As a result Heineken's aim to increase operating profit margin by 40bps p.a. over the
 medium term (through cost savings and price/mix) is credible.
- Furthermore, as the company is reporting in euro it is benefiting from a translation impact from the stronger US dollar, British pound, Vietnamese dong and Mexican peso. However, as the company hedges the US dollar for transactions 18 months ahead, the impact of exporting Heineken from Amsterdam and the Mexican beers to the US, still has to come in 2016/2017.

VALUATION

 Heineken is trading at 19.8x 2016 and 18.3x 2017 earnings compared to 22.1x and 18.4x for ABI.

NEXT CATALYSTS

20 April: trading update Heineken q1 Click here to download



Analyst: Sector Team:
Nikolaas Faes Loïc Morvan
33(0) 1 56 68 75 72 Antoine Parison
nfaes@bryangarnier.com Cédric Rossi
Virginie Roumac

Healthcare

bioMérieuxPrice EUR107.75

| Bloomberg | | BIM FP | | |
|--------------------|-----------|-----------|-------|---------|
| Reuters | | BIOX.PA | | |
| 12-month High / I | 118 | .7 / 90.8 | | |
| Market Cap (EUR | m) | | | 4,251 |
| Avg. 6m daily volu | ume (000) | | | 50.20 |
| | | | | |
| | 1 M | 3 M | 6 M 3 | 1/12/15 |
| Absolute perf. | 7.1% | -0.2% | 14.6% | -2.0% |
| Healthcare | 0.4% | -6.8% | -4.7% | -10.1% |
| DJ Stoxx 600 | -3.8% | -5.3% | -9.1% | -10.3% |
| | 2015 | 2016e | 2017e | 2018e |
| P/E | 38.5x | 26.3x | 22.2x | 18.9x |
| Div yield (%) | 0.9% | 1.0% | 1.1% | 1.3% |


Four panels now approved for use with FilmArray Torch Fair Value EUR115 (+7%)

BUY

ANALYSIS

- The FDA approved the Sepsis, Gastro-Intestinal and Meningitis-Encephalitis panels for use with BioMérieux' FilmArray Torch. Once again, the clearance of these panels came shortly after their filing (2nd half of March). The instrument should be made available in the US and in Europe by the summer and in autumn respectively, enabling bioMérieux to benefit from US hospital orders ahead of the 2016/2017 flu season.
- The recent clearance of the FilmArray Torch and its four panels alongside a push on S&M and to a lesser extent, R&D expenses, should enable bioMérieux to 1/ benefit from the window of opportunity left by GenMark to rapidly increase its footprint with a coverage that we estimate at around ~15% of targeted US hospitals. Note that GenMark has yet to communicate on the filing of its ePlex platform expected during Q2. 2/ be less dependent on volatility in the flu season from one year to the next with the ramp-up of other panels. As a reminder, sales from the GI panel which are somewhat marginal at the moment compared to the respiratory ones should fuel growth at BioFire.

The Infectious Disease Market (in USDm)



 Turning to Q1, we would expect the pace of sales growth in the quarter to be slightly softer in view of the demanding comparison basis in Q1 2015. Note that growth in China was dynamic in the first half of 2015 and that BioFire benefited from a very intense flu season. However, we would not expect this to come as a major surprise.

VALUATION

 We reiterate our BUY rating and EUR115 Fair Value (down from EUR118 following changes in our risk free rate and equity risk premium assumptions).

NEXT CATALYSTS

21st April: Q1 sales

Click here to download

Hugo Solvet, hsolvet@bryangarnier.com

Healthcare

AstraZeneca Price 4,168p

| Bloomberg | | AZN LN | | |
|-------------------|------------|--------|-------|-----------|
| Reuters | | AZN.L | | |
| 12-month High / | Low (p) | | 4,86 | 3 / 3,890 |
| Market Cap (GBF | Pm) | | | 52,698 |
| Avg. 6m daily vol | lume (000) | | | 2 542 |
| | 1 M | 3 M | 6 M 3 | 1/12/15 |
| Absolute perf. | 3.8% | -4.9% | 1.3% | -9.7% |
| Healthcare | 0.4% | -6.8% | -4.7% | -10.1% |
| DJ Stoxx 600 | -3.8% | -5.3% | -9.1% | -10.3% |
| | 2015 | 2016e | 2017e | 2018e |
| P/E | 13.8x | 14.9x | 15.3x | 14.3x |
| Div yield (%) | 4.8% | 4.8% | 4.8% | 4.8% |
| | | | | |

USD100m in externalisation revenues as AZD3293 moves to phase III Fair Value 5360p (+29%)

BUY

ANALYSIS

- AstraZeneca and Lilly jointly announced this morning that following recommendations from the independent data monitoring committee, the phase II/III study AMARANTH currently evaluating BACE inhibitor AZD3293 for early Alzheimer's disease would proceed to phase III. The IDC recommendation is based on a pre-scheduled interim safety analysis. The phase III will be named DAYBREAK and is to study AZD3293 in people with mild Alzheimer's disease and will start enrolling patients in Q3 2016.
- As a consequence of this move into phase III testing, Lilly will make a payment of USD100m to AstraZeneca, which is part of the USD500m in clinical and regulatory milestones to be paid by the potential launch of the drug. Since it is a joint development for which AstraZeneca remains exposed and strongly involved in the project, the payment will be booked as "externalisation revenue" in Q2 2016.
- Note that for Q1 2016, numbers for which are due out later this month, externalisation revenues are set to total between USD400m and USD500m, including two main payments from ProStrakan (Moventig rights in Europe, USD70m) and from CMS (Plendil rights in China, USD310m). This is very much in line with the objective to have externalisation revenues in excess of the 2015 level i.e. USD1,067m. Our estimate for 2016 is USD1,320m. The objective is also to have other operating income (OOI) in excess of the 2015 level (which was USD1.5bn) but here AstraZeneca has been less active and Q1 should be of a magnitude of USD100-150m only. We would not be surprised to see products like lesinurad sold. USD190m will be booked in Q2 from the sale of ex-US rights for Imdur.

VALUATION

· No change.

NEXT CATALYSTS

• 29th April 2016: First-quarter results - Click here to download

 $\label{lem:compact} \textit{Eric Le Berrigaud}, \textit{eleberrigaud@bryangarnier.com}$

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a BUY recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock

will feature an introduction outlining the key reasons behind the opinion.

Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to NEUTRAL be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary

event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key

reasons behind the opinion.

Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a **SELL** recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock

will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56.9% NEUTRAL ratings 35% SELL ratings 8%

Bryan Garnier Research Team

| | Dijan | Garmer 1005 | | 01111 |
|--|---------------------------|---|----------------------|---|
| Healthcare Team | Pharmaceuticals | Eric Le Berrigaud (Head of Equities) | 33 (0) 1 56 68 75 33 | eleberrigaud@bryangarnier.com |
| | Biotech/Medtech | Mickael Chane-Du | 33 (0) 1 70 36 57 45 | mchanedu@bryangarnier.com |
| | Medtech/Biotech | Hugo Solvet | 33 (0) 1 56 68 75 57 | hsolvet@bryangarnier.com |
| Consumer Team | Luxury/Consumer Goods | Loïc Morvan | 33 (0) 1 70 36 57 24 | lmorvan@bryangarnier.com |
| | Beverages | Nikolaas Faes | 33 (0) 1 56 68 75 72 | nfaes@bryangarnier.com |
| | Retailing | Antoine Parison | 33 (0) 1 70 36 57 03 | aparison@bryangarnier.com |
| | Luxury /Consumer Goods | Cedric Rossi | 33 (0) 1 70 36 57 25 | crossi@bryangarnier.com |
| | Food & Beverages | Virginie Roumage | 33 (0) 1 56 68 75 22 | vroumage@bryangarnier.com |
| TMT | Video Games / Payments | Richard-Maxime Beaudoux | 33 (0) 1 56 68 75 61 | rmbeaudoux@bryangarnier.com |
| | Telecom | Thomas Coudry | 33(0) 1 70 36 57 04 | tcoudry@bryangarnier.com |
| | Software & IT Services | Gregory Ramirez | 33 (0) 1 56 68 75 91 | gramirez@bryangarnier.com |
| | Semiconductor | Dorian Terral | 33 (0) 1 56 68 75 92 | dterral@bryangarnier.com |
| Utilities | | Xavier Caroen | 33 (0) 1 56 68 75 18 | xcaroen@bryangarnier.com |
| Insurance | | Olivier Pauchaut (Head of Research) | 33 (0) 1 56 68 75 49 | opauchaut@bryangarnier.com |
| Hotels/Business Services | | Bruno de La Rochebrochard | 33 (0) 1 56 68 75 88 | bdel arochebroch ard @bryang arnier.com |
| Construction/ Infrastructures Building Materials | | Eric Lemarié | 33 (0) 1 70 36 57 17 | elemarie@bryangarnier.com |
| Marketing | | Sophie Braincourt | 33(0) 1 56 68 75 36 | sbraincourt@bryangarnier.com |
| Market Data & Informatio | n Systems Manager | Eric Monnier | 33(0) 1 56 68 75 63 | emonnier@bryangarnier.com |

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London **Beaufort House** 15 St. Botolph Street

London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559

Financial Conduct Authority (FCA) the Autorité de Contrôle prudential et de resolution (ACPR)

Paris 26 Avenue des Champs Elysées 75008 Paris

Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01

Regulated by the Authorised and regulated by the Financial Conduct Authority (FCA) and

New York 750 Lexington Avenue

New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002

FINRA and SIPC member

Munich

Widenmayerstrasse 29 80538 Munich Germany

+49 89 2422 62 11

New Delhi The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062

+91 98 1111 5119 Fax +91 11 2621 9062

Geneva rue de Grenus 7 CP 2113

Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243

Regulated by the FINMA

This recognition is reassified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered polylegist Regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

Bryan Cannier arco identifer, regaterion normanno nominario sociosos contribujano e ellicitationo san a serio del personate el celevante caratiga, i ochedina ngaviti ano nationa de ellicitationo san a serio del personato de contributa de ellicitationo de ellici

Bright-Remite a very thinker, in superior number doctors of compilers and efforce a selectation color particular needs of including an including brains regard and including the selectation of the properties of the color particular needs of any person. This regent and including color particular needs of any person. This regent and including color particular needs of any person. This referentiary and color properties include a postion of the properties of the color particular needs of any person. This referentiary and color properties include a postion of the properties of the color particular needs of any person. This referentiary and color person the properties of the firm, or an associated companys, opinion only and no express representation or past petrol side of maintain the distinct of the firm, or an associated companys, opinion only and no express representation or past petrol side of maintain the distinct of the firm of the color particular the person that the person of the firm of the color particular the person of the firm of the color particular the person of the firm of the color particular the person of the firm of the color particular the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the firm of the color particular that the person of the color particular that the person of the color particular than the person of the person

Judgitudes the company and no extreme the compiled form of the firm, or an associated company's, opinion only and no express representation or warranty is given or not be expressed and company and no express representation or warranty is given or not be provided for the firm of any of the firm of

effect thansactions in any security discussed in this Report should call or write to our us affiliated broken, bryan Garnier securities, Electron Beauty States and the best of its knowledge, contains no misleading Non-independent place of the property of the past of the property of the past of the past of the past of its knowledge, contains no misleading Non-independent place of the past SATINGPOIS THE EVENT THE COUNTY OF THE MALE STATE OF THE COUNTY OF THE C

The First is waited half of rest harding relyings rewit be block wind uses the vacif that authors to be first in a band in the first interest and in on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000. This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....